ChoA Pharmaceutical Co., LTD. (KOSDAQ:034940)
South Korea · Delayed Price · Currency is KRW 2,725.00
-20.00 (-0.73%)
At close: Sep 11, 2026
KOSDAQ:034940 Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Other Revenue | - | - | - | - | - | -0 |
| 61,162 | 59,311 | 62,694 | 62,974 | 68,880 | 57,561 | |
Revenue Growth | 1.50% | -5.40% | -0.45% | -8.57% | 19.66% | -11.93% |
Cost of Revenue | 38,596 | 37,437 | 41,495 | 39,213 | 42,637 | 37,252 |
Gross Profit | 22,566 | 21,874 | 21,199 | 23,761 | 26,242 | 20,309 |
Selling, General & Admin | 23,798 | 25,632 | 27,089 | 26,439 | 23,940 | 23,785 |
Research & Development | 977.3 | 1,163 | 1,561 | 2,182 | 1,302 | 1,422 |
Amortization of Goodwill & Intangibles | 218.73 | 232.43 | 177.33 | 164.84 | 144 | 110.91 |
Other Operating Expenses | 607.18 | 637.83 | 671.57 | 718.68 | 672.49 | 684.56 |
Operating Expenses | 26,698 | 28,472 | 31,027 | 32,552 | 26,725 | 27,311 |
Operating Income | -4,133 | -6,598 | -9,828 | -8,792 | -482.21 | -7,003 |
Interest Expense | -1,274 | -1,190 | -1,115 | -979.33 | -676.44 | -375.65 |
Interest & Investment Income | 119.86 | 226.1 | 324.55 | 246.85 | 215.25 | 246.01 |
Earnings From Equity Investments | 21.69 | 7.09 | 14.78 | 19.86 | -4.83 | 17.96 |
Currency Exchange Gain (Loss) | 332.82 | -117.55 | 248.57 | -18.38 | 68.8 | 168.44 |
Other Non Operating Income (Expenses) | 433.6 | 383.55 | 276.16 | 316.42 | 326.3 | 118.09 |
EBT Excluding Unusual Items | -4,499 | -7,289 | -10,079 | -9,206 | -553.13 | -6,828 |
Gain (Loss) on Sale of Investments | 551.86 | 458.78 | 58.92 | 66.2 | 1.15 | 342.83 |
Gain (Loss) on Sale of Assets | 2,600 | 1,572 | 297.35 | 242.17 | 699.04 | 1,276 |
Asset Writedown | -1,166 | -1,165 | -308.15 | -2,036 | -571.44 | -1,938 |
Pretax Income | -2,513 | -6,424 | -10,031 | -10,934 | -424.38 | -7,146 |
Income Tax Expense | 843.11 | 939.65 | 136.83 | 198.7 | -939.63 | 896.29 |
Earnings From Continuing Operations | -3,356 | -7,363 | -10,168 | -11,133 | 515.25 | -8,043 |
Minority Interest in Earnings | 544.25 | 557.64 | 563.37 | 618.49 | 45.44 | -1.06 |
Net Income | -2,812 | -6,806 | -9,605 | -10,514 | 560.69 | -8,044 |
Net Income to Common | -2,812 | -6,806 | -9,605 | -10,514 | 560.69 | -8,044 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 6 | 6 | 6 | 6 | 6 | 6 |
Shares Outstanding (Diluted) | 6 | 6 | 6 | 6 | 6 | 6 |
Shares Change | -0.10% | -0.01% | 0.01% | - | - | - |
EPS (Basic) | -454.01 | -1098.42 | -1550.00 | -1696.97 | 90.49 | -1298.21 |
EPS (Diluted) | -454.01 | -1098.42 | -1550.00 | -1696.97 | 90.49 | -1298.21 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -2,859 | -6,165 | -5,019 | -2,306 | -4,225 | -5,024 |
Free Cash Flow Per Share | -461.63 | -995.08 | -810.04 | -372.24 | -681.86 | -810.86 |
Gross Margin | 36.90% | 36.88% | 33.81% | 37.73% | 38.10% | 35.28% |
Operating Margin | -6.76% | -11.13% | -15.68% | -13.96% | -0.70% | -12.17% |
Profit Margin | -4.60% | -11.47% | -15.32% | -16.70% | 0.81% | -13.97% |
Free Cash Flow Margin | -4.67% | -10.39% | -8.01% | -3.66% | -6.13% | -8.73% |
EBITDA | -1,830 | -4,167 | -7,439 | -6,405 | 1,906 | -4,109 |
EBITDA Margin | -2.99% | -7.03% | -11.87% | -10.17% | 2.77% | -7.14% |
D&A For EBITDA | 2,303 | 2,432 | 2,389 | 2,387 | 2,388 | 2,893 |
EBIT | -4,133 | -6,598 | -9,828 | -8,792 | -482.21 | -7,003 |
EBIT Margin | -6.76% | -11.13% | -15.68% | -13.96% | -0.70% | -12.17% |
Advertising Expenses | - | 1,803 | 2,560 | 847.87 | 721.26 | 1,114 |